Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AMD$520.74+54.31(+11.64%)BRIEF-AMD CEO - Now Expect Revenue to Grow More Than 80% in 20276:02:02 PM ETAMD$520.74+54.31(+11.64%)UPDATE 6-AMD forecasts 2027 sales above estimates as data-center business booms6:01:40 PM ETQCOM$166.00+4.15(+2.56%)Should You Buy Qualcomm Stock Before Its Nov. 4 Report?5:52:02 PM ETMETA$624.51+2.27(+0.36%)Meta raises $15 billion in five-part US bond sale5:50:24 PM ETPLTR$175.19-0.31(-0.18%)Is Palantir Stock a Buy After its Latest Earnings Report?5:30:02 PM ETAMD$520.74+54.31(+11.64%)UPDATE 5-AMD forecasts quarterly revenue above estimates as data-center revenue hits record5:26:51 PM ETAAPL$330.85-1.06(-0.32%)Buy the Dip in Apple or Palantir Stock After Earnings?5:26:00 PM ETAMGN$454.75-10.63(-2.28%)BUZZ-Amgen lifts 2026 profit, revenue forecasts; shares down5:06:54 PM ETMSFT$518.64+11.61(+2.29%)Microsoft: The Easy Gains Are Already Over (Downgrade)5:05:42 PM ETAMGN$454.75-10.63(-2.28%)UPDATE 1-Amgen posts higher-than-expected third quarter results, but shares dip4:59:21 PM ETNVDA$209.69+1.90(+0.91%)Tuesday's Final Takeaways: NVDA Reducing China Exposure, BE Signs California Resources MOU4:57:39 PM ETPLTR$175.19-0.31(-0.18%)Stock Market Today, Nov. 3: Palantir Falls After Q3 Results as Valuation Stays in Focus4:57:09 PM ETAMD$520.74+54.31(+11.64%)AMD Earnings 'Met the Bar,' Wedbush's Bryson Says4:52:35 PM ETAMGN$454.75-10.63(-2.28%)BUZZ-Amgen lifts 2026 profit, revenue forecast; shares down4:48:33 PM ETPLTR$175.19-0.31(-0.18%)2.5 Points Of EPS Growth Nearly Double My Palantir Valuation4:48:11 PM ETANET$191.50+27.38(+16.68%)Arista Networks Stock Pops on Q3 Earnings Beat, Strong Q4 Guidance4:47:38 PM ETAMD$520.74+54.31(+11.64%)AMD Posts Q3 Double Beat as Data Center Segment Shines, Growth Expected to 'Accelerate' in Q44:34:43 PM ETAMD$520.74+54.31(+11.64%)BUZZ-AMD rises after forecasting fourth-quarter revenue above estimates4:33:59 PM ETANET$191.50+27.38(+16.68%)BUZZ-Arista rises as Q4 sales, profit forecasts above estimates4:33:31 PM ETANET$191.50+27.38(+16.68%)Arista Revenue Up 58% as Q4 Outlook Slows: Rapid Earnings Reaction4:32:44 PM ETNOK$8.62+0.32(+3.86%)Nokia vs. Verizon: A Contrast in Revenue Scale and Seasonality4:31:11 PM ETAMD$520.74+54.31(+11.64%)EARNINGS ALERT: AMD4:30:28 PM ETLTC$45.65+0.47(+1.04%)LTC Properties Q3 revenue surges on SHOP acquisitions4:27:48 PM ETPLTR$175.19-0.31(-0.18%)Ridiculous Valuation And Vertical Chart: I Bought Palantir Anyway4:27:36 PM ET

MDWD · NASDAQ

MediWound Ltd.

$12.75 -0.77 (-5.70%)

Company overview

MediWound Ltd. is a biopharmaceutical company that develops, manufactures, and commercializes novel biotherapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, which is dead or damaged tissue in adults with deep partial- and full-thickness thermal burns, to burn centers and hospital burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds, and MW005, which is in Phase I/II clinical trials for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$165M
Employees
111
Headquarters
Yavne
Website
mediwound.com
CEO
Ofer Gonen
Listed
March 20, 2014
P/E
-5.64
Dividend yield
0.00%

Company financials

Revenue
$14.5M
Gross profit
$2.8M
Operating income
-$28M
EBITDA
-$24.2M
Net income
-$26.1M
EPS
-$2.26
Total assets
$80M
Total debt
$8.1M
Gross margin
19.61%
Net margin
-180.30%
Earnings yield
-17.73%

Revenue segmentation

By product (FY 2020)

No product segmentation.

By region (FY 2020)

Showing FY 2020

Price chart

11.5713.1214.6816.2317.79
MDWD 1D NASDAQ O13.50H13.67L13.11C13.50+0.20 (+1.50%)Vol120.42K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
MDWDMediWound Ltd. Press release MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares GlobeNewswire
MDWDMediWound Ltd. Press release MediWound to Report Third Quarter 2026 Financial Results GlobeNewswire
MDWDMediWound Ltd. Press release MediWound Awarded Additional $3.3 Million from U.S. GlobeNewswire
MDWDMediWound Ltd. Press release Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without Modification GlobeNewswire
MDWDMediWound Ltd. Press release MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference GlobeNewswire
MDWDMediWound Ltd. Stock news MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript Seeking Alpha
MDWDMediWound Ltd. Stock news MediWound Q2 Earnings Call Highlights MarketBeat
MDWDMediWound Ltd. Stock news MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates Zacks Investment Research
MDWDMediWound Ltd. Press release MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire
MDWDMediWound Ltd. Stock news MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript Seeking Alpha
MDWDMediWound Ltd. Stock news MediWound Q1 Earnings Call Highlights MarketBeat
MDWDMediWound Ltd. Stock news MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates Zacks Investment Research
MDWDMediWound Ltd. Press release MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire
MDWDMediWound Ltd. Press release MediWound to Report First Quarter 2026 Financial Results GlobeNewswire
MDWDMediWound Ltd. Stock news Head-To-Head Review: Surrozen (NASDAQ:SRZN) & MediWound (NASDAQ:MDWD) Defense World
MDWDMediWound Ltd. Press release Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement GlobeNewswire
MDWDMediWound Ltd. Press release MediWound to Present New EscharEx® Data at Leading Wound Care Conferences GlobeNewswire
MDWDMediWound Ltd. Stock news Head-To-Head Analysis: MediWound (NASDAQ:MDWD) & Dyne Therapeutics (NASDAQ:DYN) Defense World
MDWDMediWound Ltd. Press release MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million GlobeNewswire
MDWDMediWound Ltd. Stock news MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript Seeking Alpha
See more
FAQ

Questions about MediWound Ltd.

What does MediWound Ltd. do?
MediWound Ltd. is a biopharmaceutical company that develops, manufactures, and commercializes novel biotherapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, which is dead or damaged tissue in adults with deep partial- and full-thickness thermal burns, to burn centers and hospital burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds, and MW005, which is in Phase I/II clinical trials for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
What is MDWD's market cap?
MediWound Ltd. (MDWD) is a listed stock with a live quote. The latest market cap on this page is $165M.
Where is MediWound Ltd. headquartered?
MediWound Ltd. is headquartered in Yavne.
How do I get MDWD news from the API?
Call GET /v1/news?tickers=MDWD. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does MDWD news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MDWD, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the MDWD price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs